The Division of Cancer Prevention furthers the mission of the National Cancer Institute by leading, supporting, and promoting rigorous, innovative research and training to prevent cancer and its consequences to improve the health of all people.
Making cancer prevention possible
More than half of cancer survivors who were treated with chemotherapy for the four most common types of cancer experienced clinically significant hearing loss and tinnitus after treatment, according to new research.
The surprise finding emerged from a cross-sectional study published recently in the British Medical Journal Supportive & Palliative Care involving 273 patients, mostly women, who received either platinum- or taxane-containing drug regimens alone, or in combination, for the treatment of lung, breast, gastrointestinal, or gynecologic cancers. Participants were part of a larger study characterizing chemotherapy-induced peripheral neuropathy (NCT01557608).
Recruitment has begun for a clinical study that investigators hope will move “liquid biopsy” technology closer to its still-distant goal: a single blood test for the early detection of cancer. Collectively known as multi-cancer early detection (MCED) assays or sometimes multi-cancer detection assays (MCD), this new advancing technology is a promising concept for cancer screening, but there are key unanswered questions.